Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience
Future Oncology, cilt.18, sa.3, ss.323-331, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 3
- Basım Tarihi: 2022
- Doi Numarası: 10.2217/fon-2021-0303
- Dergi Adı: Future Oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.323-331
- Anahtar Kelimeler: adjuvant paclitaxel plus trastuzumab, APT trial, HER2-overexpressing breast cancer, node negative, real-life experience
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: In node-negative HER2-overexpressed breast cancers, adjuvant paclitaxel plus trastuzumab treatment is a successful de-escalation approach with excellent survival outcomes. Methods: All patients with HER2+ breast cancer treated in our centers were retrospectively reviewed. Results: We analyzed 173 patients who were treated with adjuvant paclitaxel plus trastuzumab. The mean tumor size was 2.2 cm. There were eight invasive disease events or death: four distant recurrences (2.3%), three locoregional recurrences (1.7%) and one death without documented recurrence after a 52 month follow-up. The 3-year disease-free survival and recurrence-free interval rate was 96.6%. Conclusion: This real-life experience with adjuvant paclitaxel plus trastuzumab demonstrated few distant recurrences and is compatible with the APT trial findings.